| 30.05 03:07 | dpa-AFX: Teva's AUSTEDO XR Receives FDA Approval For Once-Daily Therapy At Therapeutic Doses |
| 21.05 02:52 | dpa-AFX: Teva Says Simlandi Injection Now Available In U.S. |
| 21.05 02:33 | dpa-AFX: *TEVA AND ALVOTECH ANNOUNCE SIMLANDI INJECTION NOW AVAILABLE IN U.S |
| 15.05 14:18 | dpa-AFX: *TEVA APPOINTS MATTHEW SHIELDS AS EVP OF TEVA GLOBAL OPERATIONS, EFFECTIVE JUNE 3 |
| 08.05 13:35 | dpa-AFX: Teva And Medincell Say Phase 3 SOLARIS Study In Schizophrenia Met Primary Goal |
| 08.05 13:28 | dpa-AFX: ROUNDUP: Teva Pharmaceutical Industries Posts Narrower Loss In Q1 |
| 08.05 13:10 | dpa-AFX: Teva Pharmaceutical Industries Limited Q1 Earnings Summary |
| 08.05 13:09 | dpa-AFX: *TEVA Q1 NON-GAAP EPS $0.48 VS $0.40 PRIOR YEAR |
| 08.05 13:08 | dpa-AFX: *TEVA STILL EXPECTS FY NON-GAAP EPS TO BE $2.20 - $2.50, REVENUES OF $15.7 BLN - $16.3 BLN |
| 08.05 13:07 | dpa-AFX: *TEVA Q1 NET REVENUES $3.819 BLN VS $3.661 BLN PRIOR YEAR |
| 08.05 13:06 | dpa-AFX: *TEVA Q1 LOSS $139 MLN VS $220 MLN PRIOR YEAR |
| 08.05 13:06 | dpa-AFX: *TEVA Q1 LOSS $139 MLN VS $220 MLN PRIOR YEAR |
| 08.05 13:05 | dpa-AFX: *TEVA Q1 LOSS/SHR NARROWS TO $0.12 FROM $0.20 PRIOR YEAR |
| 08.05 13:05 | dpa-AFX: *TEVA Q1 LOSS/SHR NARROWS TO $0.12 FROM $0.20 PRIOR YEAR |
| 08.05 12:37 | dpa-AFX: *TEVA AND MEDINCELL ANNOUNCE PHASE 3 EFFICACY RESULTS FROM SOLARIS TRIAL OF TEV-'749 MEETS PRIMARY ENDPOINT |
| 08.05 12:00 | dpa-AFX: Teva Pharmaceutical Industries Q1 24 Earnings Conference Call At 8:00 AM ET |
| 30.04 11:18 | dpa-AFX: Alvotech To Manufacture Its High-concentration Interchangeable Biosimilar To Humira For Quallent |
| 30.04 10:09 | dpa-AFX: *ALVOTECH TO MANUFACTURE HIGH-CONCENTRATION INTERCHANGEABLE BIOSIMILAR TO HUMIRA FOR QUALLENT PHARMA |
| 23.04 03:07 | dpa-AFX: Supreme Court Denies Vanda Pharma' Petition In HETLIOZ Litigation Against Teva, Apotex |
| 16.04 15:05 | dpa-AFX: Teva Confirms Austedo's Effectiveness For HD Chorea With The 4-week Titration Kit |
|
|
